Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407RQ | ISIN: US81751A1088 | Ticker-Symbol: 2BO
Frankfurt
06.06.25 | 15:29
5,100 Euro
+0,99 % +0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SERINA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SERINA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SERINA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.05.Serina Therapeutics, Inc.: Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors2
22.05.Serina Therapeutics, Inc. - 8-K, Current Report1
14.05.Serina Therapeutics, Inc.: Serina Therapeutics Makes Grants to New Employees Under Inducement Plan1
09.05.Serina Therapeutics GAAP EPS of -$0.491
08.05.Serina Therapeutics, Inc.: Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights67On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform...
► Artikel lesen
08.05.Serina Therapeutics, Inc. - 8-K, Current Report-
29.04.Serina Therapeutics, Inc.: Serina Therapeutics to Present at JonesResearch Virtual CNS Day3
SERINA THERAPEUTICS Aktie jetzt für 0€ handeln
15.04.Serina Therapeutics, Inc.: Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit2
14.04.Serina Therapeutics, Inc. - 8-K, Current Report1
08.04.Serina Therapeutics closes $5 million funding for Parkinson's trial2
08.04.Serina Therapeutics, Inc.: Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease87HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug...
► Artikel lesen
07.04.Serina Therapeutics, Inc. - 8-K, Current Report-
02.04.Serina Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
24.03.Serina Therapeutics, Inc.: Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights185HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization...
► Artikel lesen
24.03.Serina Therapeutics, Inc. - 10-K, Annual Report2
24.03.Serina Therapeutics, Inc. - 8-K, Current Report-
24.03.Serina Therapeutics, Inc.: Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting1
10.03.Jones Trading sets Serina Therapeutics stock Buy rating, $11 target3
12.02.Serina Therapeutics, Inc.: Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors1
12.02.Serina Therapeutics, Inc. - 8-K, Current Report-
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1